Penn study shows that HIV drug reduces graft-versus-host disease in stem cell transplant patients:
NCI Cancer Center News
An HIV drug that redirects immune cell traffic appears to significantly reduce the dangerous complication graft-versus-host disease in blood cancer patients following allogeneic stem cell transplantation, according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American Society of Hematology Annual Meeting.
Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.